New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
06:06 EDTTMO, OSUROraSure and Thermo Fisher to launch substance abuse testing device
OraSure (OSUR) announced continued progress under its agreement with Thermo Fisher (TMO) to develop and supply homogenous fully-automated oral fluid drugs of abuse assays to be used with a new version of the company's Intercept oral fluid specimen collection device. The NIDA-5 panel of automated assays developed by Thermo Fisher and the new Intercept oral fluid specimen collection device are expected to launch in the domestic criminal justice and forensics markets in Q4. As a result of this progress, OraSure has issued its final purchase order for fully-automated assays previously developed under its now terminated collaboration with Roche Diagnostics. Under the Roche Diagnostics collaboration, which was terminated in November 2013, OraSure is entitled to receive $5.5M as a result of its submission of a final purchase order. Payment is expected to be received during Q3.
News For OSUR;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 7, 2016
20:36 EDTTMOOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
13:02 EDTTMOThermo Fisher could rise 25% or more in next year, Barron's says
Subscribe for More Information
February 3, 2016
16:56 EDTOSUROraSure sees Q1 EPS 1c-2c, consensus 1c
Subscribe for More Information
16:55 EDTOSUROraSure reports Q4 EPS 8c, consensus 3c
Reports Q4 revenue $32.4M, consensus $29.73M.
February 2, 2016
12:56 EDTOSURMizuho downplays near-term Zika revenue potential for NewLink, Intrexon
The Zika virus and its link to microcephaly and fetal brain damage have exploded into public view and lead to several drugmakers announcing plans to fight the disease, but Mizuho analyst Eric Criscuolo downplayed the potential for Zika to truly move the needle for companies in the space in the near-term. PERIPHERAL OPPORTUNITIES: NewLink (NLNK) announced plans to develop treatment options for the Zika virus as the disease was declared a global health emergency by the World Health Organization this week. While the company "could" secure funding and partnerships for the project, Criscuolo does not view NewLink's Zika plans as core to its investment story, encouraging investors to instead evaluate the company on the basis of its HyperAcute and IDO programs. Meanwhile, Intrexon's (XON) efforts in mosquito population control have also gained attention amid the rise of Zika, whose primary transmission vector is the mosquito. Though even a small slice of global mosquito spending would represent "significant" revenue for Intrexon, Criscuolo cautions that the company's program is still in early stages, with attempts at a wider rollout likely encountering political, biological, financial and public opinion hurdles. Separately, the analyst said he wouldn't be surprised to see OraSure (OSUR) also attempt to develop a Zika test given the company's response to Ebola last year, though as with NewLink, Criscuolo believes any such effort would be peripheral to OraSure's primary businesses. OTHERS TO WATCH: Other publicly traded companies involved in combating Zika include Inovio (INO) and Cerus (CERS). PRICE ACTION: Shares of NewLink are up roughly 5% to $25.63. Meanwhile, Intrexon has slipped 5.5% on Tuesday afternoon but is still up 15% over the last five trading days. Among others with links to Zika, OraSure is up fractionally, Inovio has fallen 7% and Cerus has dipped 1.4% this afternoon.
January 29, 2016
08:55 EDTTMOThermo Fisher guidance confusion creates buying opportunity, says Baird
Subscribe for More Information
07:51 EDTTMOThermo Fisher reported very storng results, guidance conservative, says Stifel
Subscribe for More Information
January 28, 2016
08:50 EDTTMOThermo Fisher sees FY16 adjusted EPS $7.80-$7.96, consensus $8.19
Subscribe for More Information
08:44 EDTTMOThermo Fisher says company has best position to address China's challenges
Subscribe for More Information
08:39 EDTTMOThermo Fisher expects to continue to face ForEx challenges in 2016
The company said it will continue to target margin expansion to 24%-26% range by 2017. Also said it will be positively impacted by temporary repeal of medical device tax. Comments taken from Q4 earnings conference call.
08:17 EDTTMOThermo Fisher reports Q4 Life Sciences revenue $1.21B
Reports Q4 Analytical Instruments revenue $925M. Reports Q4 Specialty Diagnostics revenue $865M. Repots Q4 Laboratory Products and Services revenue $1.82B.
06:04 EDTTMOThermo Fisher reports Q4 adjusted EPS $2.12, consensus $2.11
Subscribe for More Information
January 27, 2016
14:34 EDTTMONotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use